Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
915 questions in 93 reviews · Emergency and Critical Care
current versionsNo studies 141 · 15.4%Ungraded 22 · 2.4%Very low 216 · 23.6%Low 272 · 29.7%Moderate 188 · 20.5%High 76 · 8.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Olokizumab vs standard care/placebo WHO progression score (level 7 or above) D28 ‐ not reported · people with mild/moderate/severe/critical COVID‐19 Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Olokizumab vs standard care/placebo All‐cause mortality D28 · people with mild/moderate/severe/critical COVID‐19 Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane | RR 1.5 [0.55, 4.09] | 1 study · 248 participants | Very low |
Olokizumab vs standard care/placebo All‐cause mortality D60 or more ‐ not reported · people with mild/moderate/severe/critical COVID‐19 Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Olokizumab vs standard care/placebo Adverse events ‐ not reported · people with mild/moderate/severe/critical COVID‐19 Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Olokizumab vs standard care/placebo Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19 Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane | RR 1.25 [0.51, 3.06] | 1 study · 248 participants | Very low |
Siltuximab vs standard care/placebo Clinical improvement D28b · people with mild/moderate/severe/critical COVID‐19 Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane | RR 0.97 [0.79, 1.18] | 1 study · 148 participants | Very low |
Tociliuzumab vs standard care/placebo WHO progression score (level 7 or above) D28 · people with mild/moderate/severe/critical COVID‐19 Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane | RR 0.9 [0.72, 1.12] | 13 studies · 2117 participants | Low |
Siltuximab vs standard care/placebo Clinical improvement D60 or more ‐ not reported · people with mild/moderate/severe/critical COVID‐19 Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Siltuximab vs standard care/placebo WHO progression score (level 7 or above) D28 · people with mild/moderate/severe/critical COVID‐19 Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane | RR 1.97 [1.07, 3.63] | 1 study · 148 participants | Low |
Siltuximab vs standard care/placebo All‐cause mortality D28 · people with mild/moderate/severe/critical COVID‐19 Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane | RR 1.35 [0.54, 3.36] | 1 study · 148 participants | Very low |
Siltuximab vs standard care/placebo All‐cause mortality D60 or more · people with mild/moderate/severe/critical COVID‐19 Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane | RR 1.58 [0.74, 3.38] | 1 study · 148 participants | Very low |
Siltuximab vs standard care/placebo Adverse events ‐ not reported · people with mild/moderate/severe/critical COVID‐19 Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Siltuximab vs standard care/placebo Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19 Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane | RR 1.29 [0.64, 2.62] | 1 study · 148 participants | Low |
Levilimab vs standard care/placebo Clinical improvement D28b · people with mild/moderate/severe/critical COVID‐19 Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane | RR 1.53 [1.26, 1.85] | 1 study · 206 participants | Low |
Levilimab vs standard care/placebo Clinical improvement D60 or more ‐ not reported · people with mild/moderate/severe/critical COVID‐19 Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Levilimab vs standard care/placebo WHO progression score (level 7 or above) D28 ‐ not reported · people with mild/moderate/severe/critical COVID‐19 Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Levilimab vs standard care/placebo All‐cause mortality D28 · people with mild/moderate/severe/critical COVID‐19 Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane | RR 1 [0.26, 3.89] | 1 study · 206 participants | Very low |
Tociliuzumab vs standard care/placebo All‐cause mortality D28 · people with mild/moderate/severe/critical COVID‐19 Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane | RR 0.88 [0.81, 0.94] | 18 studies · 7428 participants | High |
Levilimab vs standard care/placebo All‐cause mortality D60 or more · people with mild/moderate/severe/critical COVID‐19 Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane | RR 1 [0.26, 3.89] | 1 study · 206 participants | Very low |
Levilimab vs standard care/placebo Adverse events ( · people with mild/moderate/severe/critical COVID‐19 Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane | RR 1.17 [0.73, 1.87] | 1 study · 206 participants | Low |
Levilimab vs standard care/placebo Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19 Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane | RR 0.5 [0.05, 5.43] | 1 study · 206 participants | Low |
Tociliuzumab vs standard care/placebo All‐cause mortality D60 or more · people with mild/moderate/severe/critical COVID‐19 Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane | RR 0.91 [0.8, 1.04] | 9 studies · 2775 participants | Low |
Tociliuzumab vs standard care/placebo Adverse events ( · people with mild/moderate/severe/critical COVID‐19 Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane | RR 1.03 [0.95, 1.12] | 9 studies · 1811 participants | Moderate |
Tociliuzumab vs standard care/placebo Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19 Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane | RR 0.93 [0.81, 1.07] | 16 studies · 2974 participants | Very low |
Sarilumab vs standard care/placebo Clinical improvement D28b · people with mild/moderate/severe/critical COVID‐19 Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane | RR 0.99 [0.94, 1.05] | 7 studies · 2425 participants | Moderate |
Sarilumab vs standard care/placebo Clinical improvement D60 or moree · people with mild/moderate/severe/critical COVID‐19 Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane | RR 1.22 [0.91, 1.63] | 2 studies · 239 participants | Very low |
Higher‐dose anticoagulants vs lower‐dose anticoagulants All‐cause mortality · people hospitalised with COVID‐19 Anticoagulants for people hospitalised with COVID‐19: a rapid review (2022) · Cochrane | RR 1.03 [0.92, 1.16] | 4 studies · 4489 participants | High |
Anticoagulants vs no treatment Mortality related to COVID‐19 · people hospitalised with COVID‐19 Anticoagulants for people hospitalised with COVID‐19: a rapid review (2022) · Cochrane | no estimate extracted | NR | No studies |
Anticoagulants vs no treatment Deep vein thrombosis · people hospitalised with COVID‐19 Anticoagulants for people hospitalised with COVID‐19: a rapid review (2022) · Cochrane | RR 5.67 [1.3, 24.7] | 1 study · 1403 participants | Very low |
Anticoagulants vs no treatment Pulmonary embolism · people hospitalised with COVID‐19 Anticoagulants for people hospitalised with COVID‐19: a rapid review (2022) · Cochrane | RR 24.19 [3.31, 176.53] | 1 study · 1403 participants | Very low |
Anticoagulants vs no treatment Major bleeding · people hospitalised with COVID‐19 Anticoagulants for people hospitalised with COVID‐19: a rapid review (2022) · Cochrane | RR 1.19 [0.66, 2.12] | 2 studies · 7218 participants | Very low |
Anticoagulants vs no treatment Adverse events (minor bleeding) · people hospitalised with COVID‐19 Anticoagulants for people hospitalised with COVID‐19: a rapid review (2022) · Cochrane | no estimate extracted | NR | No studies |
Higher‐dose anticoagulants vs lower‐dose anticoagulants Necessity for additional respiratory support · people hospitalised with COVID‐19 Anticoagulants for people hospitalised with COVID‐19: a rapid review (2022) · Cochrane | RR 0.54 [0.12, 2.47] | 3 studies · 3407 participants | Very low |
Higher‐dose anticoagulants vs lower‐dose anticoagulants Mortality related to COVID‐19 · people hospitalised with COVID‐19 Anticoagulants for people hospitalised with COVID‐19: a rapid review (2022) · Cochrane | no estimate extracted | NR | No studies |
Higher‐dose anticoagulants vs lower‐dose anticoagulants Deep vein thrombosis · people hospitalised with COVID‐19 Anticoagulants for people hospitalised with COVID‐19: a rapid review (2022) · Cochrane | RR 1.08 [0.57, 2.03] | 4 studies · 3422 participants | Low |
Higher‐dose anticoagulants vs lower‐dose anticoagulants Pulmonary embolism · people hospitalised with COVID‐19 Anticoagulants for people hospitalised with COVID‐19: a rapid review (2022) · Cochrane | RR 0.46 [0.31, 0.7] | 4 studies · 4360 participants | Moderate |
Higher‐dose anticoagulants vs lower‐dose anticoagulants Major bleeding · people hospitalised with COVID‐19 Anticoagulants for people hospitalised with COVID‐19: a rapid review (2022) · Cochrane | RR 1.78 [1.13, 2.8] | 4 studies · 4400 participants | Moderate |
Higher‐dose anticoagulants vs lower‐dose anticoagulants Adverse events (minor bleeding) · people hospitalised with COVID‐19 Anticoagulants for people hospitalised with COVID‐19: a rapid review (2022) · Cochrane | RR 3.28 [1.75, 6.14] | 3 studies · 1196 participants | High |
Anticoagulants vs no treatment All‐cause mortality · people hospitalised with COVID‐19 Anticoagulants for people hospitalised with COVID‐19: a rapid review (2022) · Cochrane | RR 0.64 [0.55, 0.74] | 3 studies · 8395 participants | Very low |
Anticoagulants vs no treatment Necessity for additional respiratory support · people hospitalised with COVID‐19 Anticoagulants for people hospitalised with COVID‐19: a rapid review (2022) · Cochrane | no estimate extracted | NR | No studies |
Anakinra vs standard care/placebo Clinical improvement D28 Interleukin‐1 blocking agents for treating COVID‐19 (2022) · Cochrane | RR 1.08 [0.97, 1.2] | 3 studies · 837 participants | Moderate |
Anakinra vs standard care/placebo Time to WHO Clinical Progression Score of level 7 or above Interleukin‐1 blocking agents for treating COVID‐19 (2022) · Cochrane | HR 0.69 [0.48, 0.99] | 2 studies · 722 participants | Low |
Anakinra vs standard care/placebo Time to death Interleukin‐1 blocking agents for treating COVID‐19 (2022) · Cochrane | HR 0.8 [0.59, 1.08] | 3 studies · 1518 participants | Low |
Canakinumab vs standard care/placebo Clinical improvement D28 Interleukin‐1 blocking agents for treating COVID‐19 (2022) · Cochrane | RR 1.05 [0.96, 1.14] | 2 studies · 499 participants | Moderate |
Canakinumab vs standard care/placebo Clinical improvement D60 or above Interleukin‐1 blocking agents for treating COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Canakinumab vs standard care/placebo WHO Clinical Progression Score of level 7 or above D28 Interleukin‐1 blocking agents for treating COVID‐19 (2022) · Cochrane | RR 0.72 [0.44, 1.2] | 2 studies · 499 participants | Low |
Canakinumab vs standard care/placebo WHO Clinical Progression Score of level 7 or above D60 or above Interleukin‐1 blocking agents for treating COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Canakinumab vs standard care/placebo All‐cause mortality D28 Interleukin‐1 blocking agents for treating COVID‐19 (2022) · Cochrane | RR 0.75 [0.39, 1.42] | 2 studies · 499 participants | Low |
Canakinumab vs standard care/placebo All‐cause mortality D60 or above Interleukin‐1 blocking agents for treating COVID‐19 (2022) · Cochrane | RR 0.55 [0.16, 1.91] | 1 study · 45 participants | Very low |
Canakinumab vs standard care/placebo Adverse events Interleukin‐1 blocking agents for treating COVID‐19 (2022) · Cochrane | RR 1.02 [0.86, 1.21] | 1 study · 454 participants | Moderate |